Overview

* Inhibikase Q3 net loss widens to $11.9 mln, driven by increased R&D and SG&A expenses

* Cash reserves drop to $77.3 mln from $97.5 mln at year-end 2024

Result Drivers

* EXECUTIVE TRANSITIONS - SG&A expenses rose due to executive transitions, including severance costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.13

Q3 Net -$11.9

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Inhibikase Therapeutics Inc ( IKT ) is $8.00, about 80% above its November 13 closing price of $1.60

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)